Sanofi Valuation Multiples

Sanofi Overview

About Sanofi

Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.

Founded

1994

HQ

Employees

74.8K

Website

sanofi.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $55B

EBITDA: $16B

EV

$121B

Valuation Multiples

Multiples.vc

Start free trial

Sanofi Financials

Sanofi reported last 12-month revenue of $55B and EBITDA of $16B.

In the same LTM period, Sanofi generated $39B in gross profit, $16B in EBITDA, and $12B in net income.

Sanofi P&L

In the most recent fiscal year, Sanofi reported revenue of $54B and EBITDA of $16B.

Sanofi expects next 12-month revenue of XXX and NTM EBITDA of XXX

Sanofi Stock Performance

Sanofi has current market cap of $107B, and enterprise value of $121B.

Sanofi's stock price is $44.33.

Sanofi Valuation Multiples

Sanofi trades at 2.2x EV/Revenue multiple, and 7.5x EV/EBITDA.

Sanofi Financial Valuation Multiples

As of April 2, 2026, Sanofi has market cap of $107B and EV of $121B.

Equity research analysts estimate Sanofi's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Sanofi has a P/E ratio of 9.3x.

Sanofi Margins & Growth Rates

Sanofi's revenue in the last 12 month grew by 4%.

Sanofi's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.4M for the same period.

Sanofi's rule of 40 is 34% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Sanofi's rule of X is 39% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Sanofi Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Sanofi M&A Activity

Sanofi acquired XXX companies to date.

Last acquisition by Sanofi was on XXXXXXXX, XXXXX. Sanofi acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Sanofi Investment Activity

Sanofi invested in XXX companies to date.

Sanofi made its latest investment on XXXXXXXX, XXXXX. Sanofi invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).